Refeyn’s SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterization
Announced in January 2022, Refeyn’s SamuxMP mass photometer is designed to be used with only basic training. Intended for use in adeno-associated virus (AAV) analytics, it has a mass range tailored for AAV analysis and provides accurate results in less than five minutes from sample loading to final result. Combined with low-operational costs and a small footprint, the SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterisation.
According to a company press release, the SamuxMP is designed to overcome the drawbacks of the current analytical methods by enabling users to rapidly and cost-effectively determine empty/full capsid ratios for AAVs of any serotype at the bench using very low sample volumes and concentrations with minimal sample preparation. This is intended to enhance productivity and speed up workflows through more frequent analyses in-house, making R&D and process development of gene therapies and AAV-based therapeutics significantly more efficient.
“We are delighted to announce the launch of our SamuxMP mass photometer for fast, accurate, and accessible AAV analysis”, said Anthony Fernandez, CEO, Refeyn, in the press release. “Mass photometry provides an opportunity to overcome the analytical bottleneck in the gene therapy sphere for AAV-based therapeutics and we wanted to develop an instrument that would enable a real gain in efficiency. The SamuxMP delivers precise results from the bench whilst reducing cost and preparation time. It will enable researchers to focus on what they do best, and make AAV analytics just another part of their day-to-day workflows. We look forward to working with the bioscience research community to continue delivering innovative instruments that will simplify biomolecule characterisation.”
Source: Refeyn
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.